Using Mental Health Telemetry to Predict Relapse and Re-hospitalization in Mood Disorders
PATH-MOD
1 other identifier
interventional
33
1 country
1
Brief Summary
Mood disorders -- major depression, bipolar disorder, and dysthymia -- frequently recur; they affect one in four people during their lives. At Sunnybrook, 75% of inpatient admissions are due to mood disorders. Mental health telemetry (MHT) lets patients in the community use cell phones to track the severity of their mood symptoms over time, and enables clinicians to view these symptom ratings in real-time. Evidence suggests that MHT is better for detecting exacerbations of illness earlier than standard clinical practice alone. In this study, we will assess if MHT can reduce re-hospitalization rates in previously-hospitalized patients with mood disorders.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable major-depressive-disorder
Started Oct 2013
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 18, 2013
CompletedFirst Posted
Study publicly available on registry
June 20, 2013
CompletedStudy Start
First participant enrolled
October 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2016
CompletedApril 18, 2016
April 1, 2016
2.4 years
June 18, 2013
April 14, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Re-hospitalization rate
Six months
Quality-of-life
Quality-of-Life in Bipolar Disorder (QoL.BD) self-report scale, completed at entry and bi-monthly
Six months
Secondary Outcomes (4)
Relapse rate
Six months
Participation rate
At baseline
Uptake rate
3 months
Reporting rate
6 months
Study Arms (2)
Treatment-as-usual
NO INTERVENTIONTreatment-as-usual, with no active intervention or follow-up. TAU patients will have readmission events monitored over the six-month interval by the study RA via periodic chart reviews and updates from their clinicians
Mental Health Telemetry (MHT)
EXPERIMENTALPatients in the MHT group will be encouraged to provide daily symptom self-reports using MHT. MHT patients will also have readmission events monitored over the six-month interval by the study RA via periodic chart reviews and updates from their clinicians
Interventions
Ecological momentary assessment (EMA) focuses on using data collected from subjects living their daily lives in their natural environments using minimally invasive techniques to improve the quality of the data collected. MHT is an evolution of EMA. MHT was developed at Sunnybrook in partnership with the University of Toronto; it uses cell phones to collect self-report data on symptoms of illness and then transmit it in real-time to a central database. Principal advantages of MHT over EMA include the ability to time- and date-stamp data, thus eliminating retrospective record completion, and the ability to observe and monitor data flow in real-time, without having to wait for participants to upload or deliver the data (e.g., at their next doctors' appointment).
Eligibility Criteria
You may qualify if:
- Diagnosed DSM-IV mood disorder
- Long-term follow-up at Sunnybrook
- At least two lifetime hospitalizations for mood disorders at the time of recruitment
- Own a web-enabled cell phone,
- Be willing to start or continue with mood journaling using either MHT or some other platform / medium
- Be able to be successfully trained to use MHT,
- Have provided informed consent to participate,
- Have a clinician in the Department of Psychiatry at Sunnybrook who is providing the majority of their mental health care and is participating in this study,
- In the case of participants under the age of 18 years, have the assent of at least one custodial parent and / or legal guardian
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Dr. David Kreindlerlead
- Sunnybrook Health Sciences Centrecollaborator
Study Sites (1)
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
David M Kreindler, MD
Sunnybrook Health Sciences Centre
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Staff Physician
Study Record Dates
First Submitted
June 18, 2013
First Posted
June 20, 2013
Study Start
October 1, 2013
Primary Completion
March 1, 2016
Study Completion
March 1, 2016
Last Updated
April 18, 2016
Record last verified: 2016-04